U.S. Ebola case boosts drug makers working on treatments

September 30, 2014, 6:39 PM ET

SHARE:

MORE

 

EmailPrint

Getty Images

The Ebola virus

Shares of biotechs working on treatments for Ebola rallied late Tuesday soon after the Centers for Disease Control and Prevention confirmed the first U.S. case of the deadly  virus.

The most pronounced move was in shares of Canada-based Tekmira Pharmaceuticals Inc. TKMR +30.32%. The stock surged 24% to $26.30 on very heavy volume in after-hours activity Tuesday.

In August, the Food and Drug Administration told Tekmira it would allow use of its investigational drug TKM-Ebola in patients with the virus. TKM-Ebola is in early, or Phase 1, clinical trials designed to test for safety. TKM-Ebola was also the drug taken by Richard Sacra, a U.S. doctor who recently became infected with the virus in Liberia, who recovered after returning to the U.S. for treatment.

In addition to Tekmira:

Shares of BioCryst Pharmaceuticals Inc. BCRX +14.32% rallied 11% to $10.90 on moderate volume. BioCryst is working on an Ebola treatment candidate BCX4430, and recently
consulted the World Health Organization on the virus. It also received additional federal fundingrecently to develop the drug.

Newlink Genetics Corp. NLNK +13.73% surged 13% to $24.10 on moderate volume. Earlier in the month, Newlink said the FDA gave it the green light to start Phase 1 clinical trials for its Ebola vaccine.

Sarepta Therapeutics Inc. SRPT +8.25% shares rose 7% to $22.60 on heavy volume. Sarepta is developing a treatment designated AVI-7537 to treat the Ebola virus.

Shares of drug giant GlaxoSmithKline PLC GSK +0.72% also climbed 1.1% to $46.49 on moderate volume after hours Tuesday. Glaxo is working with the National Institutes of Health’s Vaccine Research Center to help develop of an early stage vaccine for Ebola.

– Wallace Witkowski

所有跟帖： 

• 千万不要去买这些股票， 要赚钱还早， 过两天， 这些Flu都不是问题了，人会有自身的免疫能力的 -gsttt2010- ♀ (46 bytes) () 09/30/2014 postreply 20:06:03